Zimmer Biomet (ZBH) said Tuesday it now expects to repurchase up to $1 billion of its stock during fiscal year 2026, increasing its prior target by $250 million.
The company said it will execute the buybacks under its existing $1.5 billion share repurchase authorization, which its board approved in February 2026.
Zimmer Biomet did not change the size, duration or terms of the authorization, the company said.
Zimmer Biomet said it may repurchase shares through open-market purchases or structured repurchase agreements with third parties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.